Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
出版年份 2012 全文链接
标题
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
作者
关键词
-
出版物
BMC Medicine
Volume 10, Issue 1, Pages -
出版商
Springer Nature
发表日期
2012-03-23
DOI
10.1186/1741-7015-10-28
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
- (2017) Y. Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
- (2011) Gang Chen et al. BIOLOGICAL PROCEDURES ONLINE
- Current progress of siRNA/shRNA therapeutics in clinical trials
- (2011) John C. Burnett et al. Biotechnology Journal
- New therapeutic avenues in lung cancer based on disturbances in PI3K and RAS pathways
- (2011) R. Rosell EUROPEAN JOURNAL OF CANCER
- Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
- (2011) N. Sunaga et al. MOLECULAR CANCER THERAPEUTICS
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials
- (2010) Robyn P. Hickerson et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor
- (2010) K. Takezawa et al. MOLECULAR CANCER THERAPEUTICS
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
- (2010) Mark E. Davis et al. NATURE
- Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase–quantitative polymerase chain reaction
- (2009) Gang Chen et al. ANALYTICAL BIOCHEMISTRY
- Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
- (2009) J. Tabernero et al. ANNALS OF ONCOLOGY
- Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
- (2009) Shirish M. Gadgeel et al. CANCER
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell Survival
- (2009) Anurag Singh et al. CANCER CELL
- Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
- (2009) Yun Jung Choi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- The Cell Line Secretome, a Suitable Tool for Investigating Proteins Releasedin Vivoby Tumors: Application to the Study of p53-Modulated Proteins Secreted in Lung Cancer Cells
- (2009) Jérôme Chenau et al. JOURNAL OF PROTEOME RESEARCH
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
- (2009) Robert Pirker et al. LANCET
- Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations
- (2009) I. Y.-S. Tam et al. MOLECULAR CANCER THERAPEUTICS
- Amphiregulin Promotes BAX Inhibition and Resistance to Gefitinib in Non-small-cell Lung Cancers
- (2009) Benoît Busser et al. MOLECULAR THERAPY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
- (2009) Songwen ZHOU et al. RESPIROLOGY
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
- (2008) Z Tang et al. BRITISH JOURNAL OF CANCER
- A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
- (2008) E. Felip et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023
- (2008) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study
- (2008) Suresh Ramalingam et al. Journal of Thoracic Oncology
- Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells
- (2008) E. Giovannetti et al. MOLECULAR PHARMACOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- siRNA Targeting against EGFR, a Promising Candidate for a Novel Therapeutic Application to Lung Adenocarcinoma
- (2008) Sumitaka Yamanaka et al. PATHOBIOLOGY
- Modeling oncogene addiction using RNA interference
- (2008) S. M. Rothenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now